An update on disordered iron metabolism and iron overload

Deferasirox pharmacokinetics in patients with adequate versus inadequate response

(2009) D. Chirnomas et al.   BLOOD

Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells

(2009) T. Tanno et al.   BLOOD

Pancreatic iron loading predicts cardiac iron loading in thalassemia major

(2009) L. J. Noetzli et al.   BLOOD

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

(2009) Douglas B Kell   BMC Medical Genomics

Long-term sequential deferiprone-deferoxamineversusdeferiprone alone for thalassaemia major patients: a randomized clinical trial

(2009) Aurelio Maggio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daily labile plasma iron as an indicator of chelator activity inThalassaemia majorpatients

(2009) Giuliana Zanninelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia

(2009) Ali Taher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

(2009) Ali Taher et al.   BRITISH JOURNAL OF HAEMATOLOGY

A novel missense mutation inSLC40A1results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases

(2009) Emilie Létocart et al.   BRITISH JOURNAL OF HAEMATOLOGY

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

(2009) Ali Taher et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Non-transferrin bound labile plasma iron and iron overload in Sickle Cell Disease: a comparative study between Sickle Cell Disease and β thalassemic patients

(2009) Ariel Koren et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis

(2009) A. J. Ramsay et al.   HAEMATOLOGICA

Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone

(2009) P. T. Telfer et al.   HAEMATOLOGICA

High nontransferrin bound iron levels and heart disease in thalassemia major

(2008) Antonio Piga et al.   AMERICAN JOURNAL OF HEMATOLOGY

Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis

(2008) Manju Mamtani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major

(2008) John C. Wood et al.   BRITISH JOURNAL OF HAEMATOLOGY

Current Status in Iron Chelation in Hemoglobinopathies

(2008) Maria Cappellini et al.   CURRENT MOLECULAR MEDICINE

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

(2008) Shahina Daar et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron

(2008) M. A. Melis et al.   HAEMATOLOGICA

The Regulation of Hepcidin and Its Effects on Systemic and Cellular Iron Metabolism

(2008) M. D. Fleming   Hematology-American Society of Hematology Education Program

Clinical application of deferasirox: Practical patient management

(2007) Elliott Vichinsky   AMERICAN JOURNAL OF HEMATOLOGY